Zero ad trackers.We never sell your data.

Rare Disease Trial Updates: April 2026

In April 2026, Trial Friend tracked 103 rare disease clinical trial updates across 45 conditions, including 0 FDA-related actions and 14 trial status changes, alongside enrollment updates and new trial site openings sourced from ClinicalTrials.gov and FDA announcements.

This is a permanent monthly archive. For the latest updates, see the live current events feed.

Major Updates: FDA Actions, Status Changes & Results

Status ChangeEssential ThrombocythemiaApr 30thSwedish Orphan BiovitrumNCT03165734
No longer enrolling new participants

No longer enrolling new participants

Status ChangeEpidermolysis BullosaApr 30thTWi Biotechnology, Inc.NCT06073132
No longer enrolling new participants

No longer enrolling new participants

Status ChangeEosinophilic Granulomatosis with PolyangiitisApr 30thImperial College LondonNCT06230354
No longer enrolling new participants

No longer enrolling new participants

Status ChangeEosinophilic EsophagitisApr 30thUniversity of North Carolina, Chapel HillNCT06352073
No longer enrolling new participants

No longer enrolling new participants

Status ChangeAmyotrophic Lateral SclerosisApr 29thProJenXNCT05279755
No longer enrolling new participants

No longer enrolling new participants

Status ChangeUrea Cycle DisordersApr 28thBaylor College of MedicineNCT04612764
No longer enrolling new participants

No longer enrolling new participants

Status ChangeSarcoidosisApr 27thAssistance Publique - Hôpitaux de ParisNCT05689879
No longer enrolling new participants

No longer enrolling new participants

Status ChangeHemophilia AApr 24thCSL BehringNCT06738485
No longer enrolling new participants

No longer enrolling new participants

Status ChangeSickle Cell DiseaseApr 23rdAgios Pharmaceuticals, Inc.NCT06924970
No longer enrolling new participants

No longer enrolling new participants

Status ChangeDuchenne Muscular DystrophyApr 23rdNS Pharma, Inc.NCT06053814
No longer enrolling new participants

No longer enrolling new participants

Status ChangeDuchenne Muscular DystrophyApr 23rdNS Pharma, Inc.NCT06053814
No longer enrolling new participants

No longer enrolling new participants

Status ChangeIdiopathic Pulmonary FibrosisApr 23rdVicore Pharma ABNCT06588686
No longer enrolling new participants

No longer enrolling new participants

Status ChangeBecker Muscular DystrophyApr 23rdNS Pharma, Inc.NCT06053814
No longer enrolling new participants

No longer enrolling new participants

Status ChangeApr 19thVera Therapeutics, Inc.NCT07020923
No longer enrolling new participants

No longer enrolling new participants

Trial Site & Enrollment Activity

sites_addedEssential ThrombocythemiaApr 30thNovartis PharmaceuticalsNCT07357727
Added 1 new site: Seoul, South Korea

Added 1 new site: Seoul, South Korea

sites_addedCongenital Adrenal HyperplasiaApr 30thCrinetics Pharmaceuticals Inc.NCT07159841
Added 8 new sites: Córdoba, Argentina, Buenos Aires, Argentina, Edegem, Belgium and 5 more

Added 8 new sites: Córdoba, Argentina, Buenos Aires, Argentina, Edegem, Belgium and 5 more

sites_addedCongenital Adrenal HyperplasiaApr 30thCrinetics Pharmaceuticals Inc.NCT07144163
Added 8 new sites: Rochester, Minnesota, CABA, Argentina, Curitiba, Brazil and 5 more

Added 8 new sites: Rochester, Minnesota, CABA, Argentina, Curitiba, Brazil and 5 more

sites_addedEssential ThrombocythemiaApr 30thNational Cancer Institute (NCI)NCT06661915
Added 4 new sites: Palo Alto, California, Charlotte, North Carolina, Concord, North Carolina and 1 more

Added 4 new sites: Palo Alto, California, Charlotte, North Carolina, Concord, North Carolina and 1 more

sites_removedEpidermolysis BullosaApr 30thTWi Biotechnology, Inc.NCT06073132
Reduced from 36 to 30 sites

Reduced from 36 to 30 sites

Enrollment UpdateEosinophilic Granulomatosis with PolyangiitisApr 30thImperial College LondonNCT06230354
Target enrollment decreased from 66 to 42

Target enrollment decreased from 66 to 42

eligibility_changeEosinophilic Granulomatosis with PolyangiitisApr 30thImperial College LondonNCT06230354
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedEosinophilic EsophagitisApr 30thPhathom Pharmaceuticals, Inc.NCT06851559
Added 2 new sites: Boston, Massachusetts, New York, New York

Added 2 new sites: Boston, Massachusetts, New York, New York

Enrollment UpdateEosinophilic EsophagitisApr 30thUniversity of North Carolina, Chapel HillNCT06352073
Target enrollment decreased from 30 to 23

Target enrollment decreased from 30 to 23

sites_addedDuchenne Muscular DystrophyApr 30thInsmed Gene Therapy LLCNCT06817382
Added 1 new site: Los Angeles, California

Added 1 new site: Los Angeles, California

sites_addedDilated CardiomyopathyApr 30thKardigan, Inc.NCT07210723
Added 7 new sites: New York, New York, Houston, Texas, Copenhagen, Denmark and 4 more

Added 7 new sites: New York, New York, Houston, Texas, Copenhagen, Denmark and 4 more

sites_addedDermatomyositisApr 30thCabaletta BioNCT06154252
Added 2 new sites: Salt Lake City, Utah, Milwaukee, Wisconsin

Added 2 new sites: Salt Lake City, Utah, Milwaukee, Wisconsin

Enrollment UpdateCystic FibrosisApr 30thSheffield Teaching Hospitals NHS Foundation TrustNCT07192679
Target enrollment decreased from 80 to 60

Target enrollment decreased from 80 to 60

sites_addedCholangiocarcinomaApr 30thMacroGenicsNCT06723236
Added 1 new site: Boston, Massachusetts

Added 1 new site: Boston, Massachusetts

eligibility_changeCDKL5 Deficiency DisorderApr 30thZogenix, Inc.NCT05064878
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedBecker Muscular DystrophyApr 29thInsmed Gene Therapy LLCNCT06817382
Added 1 new site: Los Angeles, California

Added 1 new site: Los Angeles, California

sites_addedAmyotrophic Lateral SclerosisApr 29thInsmed Gene Therapy LLCNCT07290062
Added 2 new sites: La Jolla, California, Palo Alto, California

Added 2 new sites: La Jolla, California, Palo Alto, California

sites_addedATTR Amyloidosis (Transthyretin Amyloidosis)Apr 29thAlnylam PharmaceuticalsNCT07358078
Added 1 new site: Boston, Massachusetts

Added 1 new site: Boston, Massachusetts

sites_addedATTR Amyloidosis (Transthyretin Amyloidosis)Apr 29thNovo Nordisk A/SNCT07207811
Added 7 new sites: Santa Rosa, California, Ann Arbor, Michigan, Philadelphia, Pennsylvania and 4 more

Added 7 new sites: Santa Rosa, California, Ann Arbor, Michigan, Philadelphia, Pennsylvania and 4 more

eligibility_changeATTR Amyloidosis (Transthyretin Amyloidosis)Apr 29thNovo Nordisk A/SNCT07207811
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedAngelman SyndromeApr 29thIonis Pharmaceuticals, Inc.NCT06914609
Added 1 new site: Atlanta, Georgia

Added 1 new site: Atlanta, Georgia

sites_addedAmyotrophic Lateral SclerosisApr 29thPrileniaNCT07322003
Added 2 new sites: Fairway, Kansas, Montreal, Canada

Added 2 new sites: Fairway, Kansas, Montreal, Canada

sites_addedAmyotrophic Lateral SclerosisApr 29thMerit E. Cudkowicz, MDNCT04297683
Added 2 new sites: Westerville, Ohio, Austin, Texas

Added 2 new sites: Westerville, Ohio, Austin, Texas

sites_addedAlpha-1 Antitrypsin DeficiencyApr 29thAIRNA CorporationNCT07431112
Added 2 new sites: Tbilisi, Georgia, Tbilisi, Georgia

Added 2 new sites: Tbilisi, Georgia, Tbilisi, Georgia

sites_addedAchondroplasiaApr 29thTyra Biosciences, IncNCT06842355
Added 1 new site: Vitoria-Gasteiz, Spain

Added 1 new site: Vitoria-Gasteiz, Spain

eligibility_changeThalassemiaApr 28thUniversitair Ziekenhuis BrusselNCT05414045
Eligibility criteria have been updated

Eligibility criteria have been updated

eligibility_changeSpinal Muscular AtrophyApr 28thAssistance Publique - Hôpitaux de ParisNCT06147414
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedSickle Cell DiseaseApr 27thNovartis PharmaceuticalsNCT06546670
Added 2 new sites: Birmingham, Alabama, Boston, Massachusetts

Added 2 new sites: Birmingham, Alabama, Boston, Massachusetts

sites_addedPulmonary Arterial HypertensionApr 27thAllRock Bio, Inc.NCT07175038
Added 1 new site: Rancho Cordova, California

Added 1 new site: Rancho Cordova, California

Enrollment UpdateSickle Cell DiseaseApr 27thForma Therapeutics, Inc.NCT06198712
Target enrollment increased from 50 to 95

Target enrollment increased from 50 to 95

eligibility_changeSickle Cell DiseaseApr 27thForma Therapeutics, Inc.NCT06198712
Eligibility criteria have been updated

Eligibility criteria have been updated

Enrollment UpdateSarcoidosisApr 27thAssistance Publique - Hôpitaux de ParisNCT05689879
Target enrollment decreased from 90 to 32

Target enrollment decreased from 90 to 32

Enrollment UpdatePrader-Willi SyndromeApr 27thMaimonides Medical CenterNCT05939453
Target enrollment increased from 30 to 50

Target enrollment increased from 30 to 50

sites_addedPolycystic Kidney DiseaseApr 27thVertex Pharmaceuticals IncorporatedNCT07161037
Added 2 new sites: New York, New York, Seattle, Washington

Added 2 new sites: New York, New York, Seattle, Washington

sites_addedPhenylketonuriaApr 27thOtsuka Pharmaceutical Development & Commercialization, Inc.NCT06637514
Added 7 new sites: Gainesville, Florida, Tampa, Florida, Portland, Oregon and 4 more

Added 7 new sites: Gainesville, Florida, Tampa, Florida, Portland, Oregon and 4 more

sites_addedPhenylketonuriaApr 27thPTC TherapeuticsNCT05166161
Added 1 new site: South Brisbane, Australia

Added 1 new site: South Brisbane, Australia

sites_addedParoxysmal Nocturnal HemoglobinuriaApr 27thRegeneron PharmaceuticalsNCT07154745
Added 1 new site: Seoul, South Korea

Added 1 new site: Seoul, South Korea

sites_addedMyelodysplastic SyndromesApr 26thAstraZenecaNCT07155226
Added 1 new site: Chapel Hill, North Carolina

Added 1 new site: Chapel Hill, North Carolina

sites_addedMyasthenia GravisApr 26thNovartis PharmaceuticalsNCT06744920
Added 4 new sites: Salvador, Brazil, Hamburg, Germany, Gurugram, India and 1 more

Added 4 new sites: Salvador, Brazil, Hamburg, Germany, Gurugram, India and 1 more

sites_addedMultiple SclerosisApr 26thNovartis PharmaceuticalsNCT07225504
Added 44 new sites: Maitland, Florida, Smyrna, Georgia, Spokane, Washington and 41 more

Added 44 new sites: Maitland, Florida, Smyrna, Georgia, Spokane, Washington and 41 more

sites_addedMembranous NephropathyApr 25thVertex Pharmaceuticals IncorporatedNCT07204275
Added 7 new sites: Porto Alegre, Brazil, Baotou, China, Changchun, China and 4 more

Added 7 new sites: Porto Alegre, Brazil, Baotou, China, Changchun, China and 4 more

sites_addedHemophilia AApr 24thNovo Nordisk A/SNCT07220564
Added 11 new sites: Brussels, Belgium, Bron, France, Katowice, Poland and 8 more

Added 11 new sites: Brussels, Belgium, Bron, France, Katowice, Poland and 8 more

sites_addedGraves’ DiseaseApr 24thMerida BiosciencesNCT07305818
Added 1 new site: Boston, Massachusetts

Added 1 new site: Boston, Massachusetts

sites_addedGeographic AtrophyApr 24thRegeneron PharmaceuticalsNCT07230834
Added 1 new site: Dallas, Texas

Added 1 new site: Dallas, Texas

eligibility_changeGastrointestinal Stromal TumorApr 24thCentre Leon BerardNCT05152472
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedFabry DiseaseApr 24thAmicus TherapeuticsNCT06904261
Added 2 new sites: Minneapolis, Minnesota, Charlotte, North Carolina

Added 2 new sites: Minneapolis, Minnesota, Charlotte, North Carolina

eligibility_changeHemophilia BApr 24thAssistance Publique - Hôpitaux de ParisNCT06147414
Eligibility criteria have been updated

Eligibility criteria have been updated

eligibility_changeHemophilia AApr 24thAssistance Publique - Hôpitaux de ParisNCT06147414
Eligibility criteria have been updated

Eligibility criteria have been updated

eligibility_changeFragile X SyndromeApr 24thAssistance Publique - Hôpitaux de ParisNCT06147414
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedFocal Segmental GlomerulosclerosisApr 24thAkebia TherapeuticsNCT07268638
Added 2 new sites: Pontiac, Michigan, Dallas, Texas

Added 2 new sites: Pontiac, Michigan, Dallas, Texas

sites_removedSickle Cell DiseaseApr 23rdAgios Pharmaceuticals, Inc.NCT06924970
Reduced from 32 to 30 sites

Reduced from 32 to 30 sites

eligibility_changeSickle Cell DiseaseApr 23rdUniversitair Ziekenhuis BrusselNCT05414045
Eligibility criteria have been updated

Eligibility criteria have been updated

eligibility_changeSickle Cell DiseaseApr 23rdAssistance Publique - Hôpitaux de ParisNCT06147414
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedRetinitis PigmentosaApr 23rdZhongshan Ophthalmic Center, Sun Yat-sen UniversityNCT07126470
Added 2 new sites: Shenzhen, China, Wuhan, China

Added 2 new sites: Shenzhen, China, Wuhan, China

eligibility_changePolycystic Kidney DiseaseApr 23rdAssistance Publique - Hôpitaux de ParisNCT06147414
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedMyelodysplastic SyndromesApr 23rdNational Cancer Institute (NCI)NCT05554406
Added 1 new site: Stony Brook, New York

Added 1 new site: Stony Brook, New York

sites_addedMyasthenia GravisApr 23rdargenxNCT07284420
Added 4 new sites: Leuven, Belgium, Bydgoszcz, Poland, Katowice, Poland and 1 more

Added 4 new sites: Leuven, Belgium, Bydgoszcz, Poland, Katowice, Poland and 1 more

sites_addedMyasthenia GravisApr 23rdargenxNCT07294170
Added 5 new sites: Leuven, Belgium, Bydgoszcz, Poland, Krakow, Poland and 2 more

Added 5 new sites: Leuven, Belgium, Bydgoszcz, Poland, Krakow, Poland and 2 more

sites_addedMultiple SclerosisApr 23rdHoffmann-La RocheNCT07282574
Added 17 new sites: Bordeaux, France, Toulouse, France, Montpellier, France and 14 more

Added 17 new sites: Bordeaux, France, Toulouse, France, Montpellier, France and 14 more

sites_addedEssential ThrombocythemiaApr 23rdMerck Sharp & Dohme LLCNCT06079879
Added 1 new site: Eugene, Oregon

Added 1 new site: Eugene, Oregon

sites_addedDuchenne Muscular DystrophyApr 23rdNS Pharma, Inc.NCT06053814
Added 1 new site: Sendai, Japan

Added 1 new site: Sendai, Japan

eligibility_changeDuchenne Muscular DystrophyApr 23rdNS Pharma, Inc.NCT06053814
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedDuchenne Muscular DystrophyApr 23rdSatellos Bioscience, Inc.NCT06867107
Added 1 new site: Melbourne, Australia

Added 1 new site: Melbourne, Australia

eligibility_changeDuchenne Muscular DystrophyApr 23rdAssistance Publique - Hôpitaux de ParisNCT06147414
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedDuchenne Muscular DystrophyApr 23rdNS Pharma, Inc.NCT06053814
Added 1 new site: Sendai, Japan

Added 1 new site: Sendai, Japan

eligibility_changeDuchenne Muscular DystrophyApr 23rdNS Pharma, Inc.NCT06053814
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedDuchenne Muscular DystrophyApr 23rdSatellos Bioscience, Inc.NCT06867107
Added 1 new site: Melbourne, Australia

Added 1 new site: Melbourne, Australia

eligibility_changeDuchenne Muscular DystrophyApr 23rdAssistance Publique - Hôpitaux de ParisNCT06147414
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedMembranous NephropathyApr 23rdBiogenNCT06962800
Added 2 new sites: Nanning, China, New Delhi, India

Added 2 new sites: Nanning, China, New Delhi, India

sites_addedDermatomyositisApr 23rdargenxNCT05979441
Added 6 new sites: Tampa, Florida, Beijing, China, Shanghai, China and 3 more

Added 6 new sites: Tampa, Florida, Beijing, China, Shanghai, China and 3 more

sites_addedDermatomyositisApr 23rdargenxNCT05979441
Added 6 new sites: Tampa, Florida, Beijing, China, Shanghai, China and 3 more

Added 6 new sites: Tampa, Florida, Beijing, China, Shanghai, China and 3 more

eligibility_changeCystic FibrosisApr 23rdAssistance Publique - Hôpitaux de ParisNCT06147414
Eligibility criteria have been updated

Eligibility criteria have been updated

eligibility_changeCystic FibrosisApr 23rdAssistance Publique - Hôpitaux de ParisNCT06147414
Eligibility criteria have been updated

Eligibility criteria have been updated

eligibility_changeChronic Inflammatory Demyelinating PolyneuropathyApr 23rdTakedaNCT06798012
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedChronic Inflammatory Demyelinating PolyneuropathyApr 23rdargenxNCT07264426
Added 4 new sites: Bochum, Germany, Bochum, Germany, Cologne, Germany and 1 more

Added 4 new sites: Bochum, Germany, Bochum, Germany, Cologne, Germany and 1 more

sites_addedIdiopathic Pulmonary FibrosisApr 23rdRein TherapeuticsNCT06968845
Added 2 new sites: Kansas City, Missouri, Sosnowiec, Poland

Added 2 new sites: Kansas City, Missouri, Sosnowiec, Poland

sites_removedIdiopathic Pulmonary FibrosisApr 23rdVicore Pharma ABNCT06588686
Reduced from 117 to 111 sites

Reduced from 117 to 111 sites

eligibility_changeHuntington DiseaseApr 23rdAssistance Publique - Hôpitaux de ParisNCT06147414
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedBecker Muscular DystrophyApr 23rdNS Pharma, Inc.NCT06053814
Added 1 new site: Sendai, Japan

Added 1 new site: Sendai, Japan

eligibility_changeBecker Muscular DystrophyApr 23rdNS Pharma, Inc.NCT06053814
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedBecker Muscular DystrophyApr 23rdSatellos Bioscience, Inc.NCT06867107
Added 1 new site: Melbourne, Australia

Added 1 new site: Melbourne, Australia

eligibility_changeBecker Muscular DystrophyApr 23rdAssistance Publique - Hôpitaux de ParisNCT06147414
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedAchondroplasiaApr 23rdTyra Biosciences, IncNCT06842355
Added 1 new site: Houston, Texas

Added 1 new site: Houston, Texas

sites_addedAmyotrophic Lateral SclerosisApr 22ndBeth Israel Deaconess Medical CenterNCT06491732
Added 5 new sites: Phoenix, Arizona, Boston, Massachusetts, Ann Arbor, Michigan and 2 more

Added 5 new sites: Phoenix, Arizona, Boston, Massachusetts, Ann Arbor, Michigan and 2 more

eligibility_changeAmyotrophic Lateral SclerosisApr 22ndBeth Israel Deaconess Medical CenterNCT06491732
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedApr 19thHoffmann-La RocheNCT05797610
Added 2 new sites: San Jose, California, Berlin, Germany

Added 2 new sites: San Jose, California, Berlin, Germany

sites_addedApr 19thTakedaNCT06963827
Added 4 new sites: Budapest, Hungary, Maribor, Slovenia, Fatih, Turkey (Türkiye) and 1 more

Added 4 new sites: Budapest, Hungary, Maribor, Slovenia, Fatih, Turkey (Türkiye) and 1 more

sites_addedApr 19thBiogenNCT06935357
Added 5 new sites: Gainesville, Florida, Fuzhou, China, Heraklion, Greece and 2 more

Added 5 new sites: Gainesville, Florida, Fuzhou, China, Heraklion, Greece and 2 more

sites_addedApr 19thVertex Pharmaceuticals IncorporatedNCT06154447
Added 2 new sites: Orlando, Florida, Billings, Montana

Added 2 new sites: Orlando, Florida, Billings, Montana